Purine metabolism and hyperuricemic states: 'The point of view of the rheumatologist'

Contributions to Nephrology

Volumn 147, Issue , 2005, Pages 1-21

  Peronato, Giovanni ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PURINE; PURINE DERIVATIVE;

GOUT; HUMAN; HYPERURICEMIA; METABOLISM; REVIEW;

GOUT; HUMANS; HYPERURICEMIA; PURINES;

EID: 16644402228     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (78)

1. Pal B, Foxall M, Dysart T, Carey F, Whiltaker M: How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol 2000;19:21-25.
2. Woo J, Cannon DC: Metabolic intermediates and inorganic ions; in Todd, Sanford, Davidson (eds): Clinical Diagnosis and Management by Laboratory Methods, ed 6. Philadelphia, WB Saunders Company, 1984, pp 133-164.
3. Agudelo CA, Wise CM: Gout: Diagnosis, pathogenesis, and clinical manifestations. Curr Opin Rheumatol 2001;13:234-239.
4. Johnson RJ, Rideout BA: Uric acid and diet - Insights into cardiovascular disease. N Engl J Med 2004;350:1071-1073.
5. Watanabe S, Kang D-H, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson RJ: Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002;40:355-360.
6. Squadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu RM, Pryor WA: Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 2000;376:333-337.
7. Roubenoff R: Gout and hyperuricemia. Rheum Dis Clin North Am 1990;16:539-550.
8. Terkeltaub RA: Gout. N Engl J Med 2003;349:1647-1655.
9. Lawrence CG, Helmick FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe FP: Prevalence of musculoskeletal disorders. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-799.
10. Rott KT, Agudelo CA: Gout. JAMA 2003;289:2857-2860.
11. Campion EW, Glynn RJ, DeLabry LO: Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987;82:421-426.
12. Lin KC, Lin HY, Chou P: The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000;27:1501-1505.
13. Pascual E, Pedraz T: Gout. Curr Opin Rheumatol 2004;16:282-286.
14. Wortmann RL: Gout and hyperuricemia. Curr Opin Rheumatol 2002;14:281-286.
15. Wortmann RL, Kelley WN: Gout and hyperuricemia; in Ruddy S, Harris ED, Sledge CB (eds): Kelley's Textbook of Rheumatology, ed 6. Philadelphia, Saunders, 2001, pp 1339-1376.
16. Cohen MG, Emmerson BT: Gout; in Klippel JH, Dieppe PA (eds): Rheumatology, ed 2. London, Mosby, 1998, p 8/14.1-14.
17. Boss GR, Seegmiller JE: Hyperuricemia and gout. N Engl J Med 1979;300:1439-1468.
18. Simkin PA: The pathogenesis of podagra. Ann Intern Med 1977;86:230-233.
19. Pascual E, Batlle-Gualda E, Martinez A, Rosas J, Vela P: Urate crystals in synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med 1999;131:756-759.
20. Yu T: Gout; in Katz WA (ed): Diagnosis and Management of Rheumatic Diseases, ed 2. Philadelphia, Lippincott Comp, 1988, pp 544-561.
21. Liu R, O'Connell M, Johnson K, Pritzker K, Mackman N, Terkeltaub R: Extracellular signal-regulated kinase 1/extracellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappaB transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells. Arthritis Rheum 2000;43:1145-1155.
22. Schumacher HR, Phelps P: Sequential changes in human polymorphonuclear leukocytes after urate crystal phagocytosis. An electron microscopic study. Arthritis Rheum 1971;14:513-526.
23. Nuki G: Crystal arthropathies; in Maddison PJ, Isemberg DA, Woo P, Glass DN (eds): Oxford Textbook of Rheumatology. Oxford University Press, 1993, pp 983-1005.
24. Morgan MP, McCarthy GM: Signaling mechanism involved in crystal-induced tissue damage. Curr Opin Rheumatol 2002;14:292-297.
25. Tudan C, Fong D, Duronio V, Burt HM, Jackson JK: The inhibition of spontaneous and tumor necrosis factor-alpha induced neutrophil apoptosis by crystals of calcium pyrophosphate dihydrate and monosodium urate monohydrate. J Rheumatol 2000;27:2463-2472.
26. Landis RC, Yagnik DR, Florey O, Philippidis P, Emons V, Mason JC, Haskard DO: Safe disposal of inflammatory monosodium urate monohydrate crystals by differentiated macrophages. Arthritis Rheum 2002;46:3026-3033.
27. Yagnik DR, Hillyer P, Marshall D, Smythe CD, Krausz T, Haskard DO, Landis RC: Noninflammatory phagocytosis of monosodium urate monohydrate crystals by mouse macrophages. Implications for the control of joint inflammation in gout. Arthritis Rheum 2000;43:1779-1789.
28. Seegmiller JE, Rosenbloom EM, Kelley WN: An enzyme defect associated with sex-linked neurological disorder and excessive purine synthesis. Science 1967;155:561-567.
29. Sperling O, Eilam G, Persky-Brosh S, De Vries A: Accelerated erythrocyte-5-phosphoribosyl-1-pyrophosphatase synthesis. A familiar abnormality associated with excessive uric acid production and gout. Biochem Med 1972;6:310-316.
30. Dieppe PA: Investigation and management of gout in the young and the elderly. Ann Rheum Dis 1991;50:263-266.
31. Mineo I, Kono N, Hara N, Shimizu T, Yamada Y, Kawachi M, Kiyokawa H, Wang YL, Tarui S: Myogenic hyperuricemia. A common pathophysiologic feature of glycogenosis types III, V, and VII. N Engl J Med 1987;317:75-80.
32. Puig JG, Mateos FA, Miranda ME, Torres RJ, de Miguel E, Perez de Ayala C, Gil AA: Purine metabolism in women with primary gout. Am J Med 1994;97:332-338.
33. Emmerson BT, Nagel SL, Duffy DL, Martin NG: Genetic control of the renal clearance of urate: A study of twins. Ann Rheum Dis 1992;51:375-377.
34. Calabrese G, Simmonds HA, Cameron JS, Davies PM: Precocious familial gout with reduced fractional urate clearance and normal purine enzymes. Q J Med 1990;75:441-450.
35. Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R: The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 2000;43:103-108.
36. Resnick D, Niwayama G: Gouty arthritis; in Resnick D, Niwayama G (eds): Diagnosis of Bone and Joint Disorders, ed 2. Philadelphia, WB Saunders Company, 1988, pp 1619-1671.
37. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF: Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
38. McCarty DJ, Hollander JL: Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961;54:452-460.
39. O'Connell PG, Milburn BM, Nashel DJ: Coexistent gout and septic arthritis: A report of two cases and literature review. Clin Exp Rheumatol 1985;3:265-267.
40. Humphreys W: The painful red foot - Inflammation or ischaemia? Br Med J 1999;318:925-926.
41. Yu TF: Diversity of clinical features in gouty arthritis. Semin Arthritis Rheum 1984;13:360-368.
42. ter Borg EJ, Rasker JJ: Gout in the elderly, a separate entity? Ann Rheum Dis 1987;46:72-76.
43. Doherty M, Dieppe P: Crystal deposition disease in the elderly. Clin Rheum Dis 1986;12:97-116.
44. Park YB, Park YS, Song J, Lee WK, Suh CH, Lee SK: Clinical manifestations of Korean female gouty patients. Clin Rheumatol 2000;19:142-146.
45. Alderman MH, Cohen H, Madhavan S, Kivlighn S: Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999;34:144-150.
46. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Turtle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183-1190.
47. Waring WS, Webb DJ, Maxwell SRJ: Uric acid as a risk factor for cardiovascular disease. Q J Med 2000;93:707.
48. Verdecchia P, Schillaci G, Reboldi GP, Santeusanio F, Porcellati C, Brunetti P: Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: The PIUMA Study. Hypertension 2000;36:1072-1078.
49. Ward HJ: Uric acid as an independent risk factor in the treatment of hypertension. Lancet 1998; 352:670-671.
50. Liese AD, Hense HW, Lowel H, Doring A, Tietze M, Keil U: Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology 1999;10:391-397.
51. Bengtsson C, Lapidus L, Stendahl C, Waldestrom J: Hyperuricaemia and risk of cardiovascular disease and overall death. A 12 year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand 1988;224:549-555.
52. Puddu PE, Lanti M, Menotti A, Mancini M, Zanchetti A, Cirillo M, Angeletti M, Panarelli W: Gubbio Study Research Group. Serum uric acid for short-term prediction of cardiovascular disease incidence in the Gubbio Population Study. Acta Cardiol 2001;56:243-251.
53. Wannamethee SG, Shaper AG, Whincup PH: Serum urate and the risk of major coronary heart disease events. Heart 1997;78:147-153.
54. Culleton BF, Larson MG, Kannel WB, Levy D: Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 1999;131:7-13.
55. Zavaroni I, Mazza S, Fantuzzi M, Dall'Aglio E, Bonora E, Delsignore R, Passeri M, Reaven GM: Changes in insulin and lipid metabolism in males with asymptomatic hyperuricaemia. J Intern Med 1993;234:25-30.
56. Muscelli E, Natali A, Bianchi S, Bigazzi R, Galvan AQ, Sironi AM, Frascerra S, Ciociaro D, Ferrannini E: Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 1996;9:746-752.
57. Chou P, Lin KC, Lin HY, Tsai ST: Gender differences in the relationships of serum uric acid with fasting serum insulin and plasma glucose in patients without diabetes. J Rheumatol 2001;28:571-576.
58. Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J: Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: A pilot study. Ann Rheum Dis 2000;59:539-543.
59. Tsunoda S, Kamide K, Minami J, Kawano Y: Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: Effect of a low-energy diet and an insulin-sensitizing agent. Am J Hypertens 2002;15:697-701.
60. Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-1899.
61. Schumacher RH, Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, Tate GA, Molina J: Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. Br Med J 2002;324:1488-1492.
62. Rubin BR, Burton R, Navarra S, Antigua J, Londoño J, Pryhuber KG, Lund M, Chen E, Najarian DK, Petruschke RA, Ozturk ZE, Geba GP: Efficacy and safety profile of treatment with Etoricoxib 120 mg once daily compared with Indomethacin 50 mg three times daily in acute gout. Arthritis Rheum 2004;50:598-606.
63. Pouliot M, James MJ, McColl SR, Naccache PH, Cleland LG: Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. Blood 1998;91:1769-1776.
64. Emmerson BT: The management of gout. N Engl J Med 1996;334:445-451.
65. Morris I, Varughese G, Mattingly P: Lesson of the week - Colchicine in acute gout. Br Med J 2003;327:1275-1276.
66. Schlesinger N, Schumacher HR: Gout: Can management be improved? Curr Opin Rheumatol 2001;13:240-244.
67. Pascual E, Castellano JA: Treatment with colchicine decreases white cell counts in synovial fluid of asymptomatic knees that contain monosodium urate crystals. J Rheumatol 1992;19:600-603.
68. Scott JT, Higgens CS: Diuretic induced gout: A multifactorial condition. Ann Rheum Dis 1992;51:259-261.
69. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G: Purine-Rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004;350:1093-1103.
70. Choi HK, Atkinson K, Karlson EW, Willett A, Curhan G: Alcohol intake and risk of incident gout in men: Aprospective study. Lancet 2004;363:1277-1281.
71. Jelley MJ, Wortmann R: Practical steps in the diagnosis and management of gout. BioDrugs 2000;14:99-107.
72. Ettinger B, Tang A, Citron JT, Livermore B, Williams T: Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 1986;315:1386-1389.
73. American College of Rheumatology [homepage on the Internet], Mahowald ML: Overview of the evaluation and management of gout and hyperuricemia. Available from: http://www.rheumatology. org/publications/primarycare/number4/hrh0021498. asp
74. Arellano F, Sacristan JA: Allopurinol hypersensitivity syndrome: A review. Ann Pharmacother 1993;27:337-343.
75. Sica DA, Schoolwerth AC: Uric acid and losartan. Curr Opin Nephrol Hypertens 2002;11:475-482.
76. Alderman M, Aiyer KJ: Uric acid: Role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004;20:369-379.
77. Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M: Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003;62:572-575.
78. Bomalaski JS, Goddard DH, Grezlak D, et al: Phase I study of uricase formulated with polyethylene glycol (Uricase PEG 20) (abstract). Arthritis Rheum 2002;46:S141.